← All trials
NCT05287321
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 15, 2022
- Primary completion
- Apr 15, 2024
- Completion date
- Apr 15, 2025
- First posted
- Mar 18, 2022
- Last posted
- Mar 18, 2022
- Enrollment
- 122
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chung-Ang UniversityLead sponsor
- Chung-Ang UniversityOverall official - principal investigator
- Chung-Ang UniversitySponsor investigator
- Government of KoreaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.